✦ LIBER ✦

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

✍ Scribed by Garcia-Manero, G.; Kantarjian, H. M.; Sanchez-Gonzalez, B.; Yang, H.; Rosner, G.; Verstovsek, S.; Rytting, M.; Wierda, W. G.; Ravandi, F.; Koller, C.; Xiao, L.; Faderl, S.; Estrov, Z.; Cortes, J.; O'Brien, S.; Estey, E.; Bueso-Ramos, C.; Fiorentino, J.; Jabbour, E.; Issa, J.-P.

Book ID: 125521171
Publisher: American Society of Hematology
Year: 2006
Tongue: English
Weight: 241 KB
Volume: 108
Category: Article
ISSN: 0006-4971
DOI: 10.1182/blood-2006-03-009142

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of 5-aza-2′-deoxycytidine

Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer

✍ B. F. Chu, M. J. Karpenko, Z. Liu, J. Aimiuwu… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 298 KB

Phase I study on 5-aza-2′-deoxycytidine

Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia

✍ Georges E. Rivard; Richard L. Momparler; Jocelyn Demers; Paul Benoit; Richard Ra 📂 Article 📅 1981 🏛 Elsevier Science 🌐 English ⚖ 709 KB

Phase I study on 5-aza-2′-deoxycytidine

Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia

✍ Georges E. Rivard; Richard L. Momparler; Jocelyn Demers; Paul Benoit; Richard Ra 📂 Article 📅 1981 🏛 Elsevier Science 🌐 English ⚖ 709 KB

Ahstract--A Phase I study with 5-aza-2'-deoxycytidine (5-AZA-CdR) was performed on children with acute leukemia who were resistant to conventional chemotherapy. The objective of this study was to find the dose-schedule of 5-AZA-CdR that produced a potent antileukemic effect and to evaluate its toxic

Results of decitabine (5-aza-2′deoxycyti

Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

✍ Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Francis J. Giles; Stefan Fader 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

## Abstract ## BACKGROUND General and site‐specific DNA methylation is associated with tumor progression and resistance in several cancers, including chronic myelogenous leukemia (CML). Decitabine is a hypomethylating agent that has shown encouraging preliminary anti‐CML activity. This study evalu

Valproic acid, in combination with all-t

Valproic acid, in combination with all-trans retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARβ2 in breast cancer cells

✍ Mongan, Nigel P. (author);Gudas, Lorraine J. (author) 📂 Article 📅 2005 🏛 American Association for Cancer Research (AACR) 🌐 English ⚖ 482 KB

Combinational chemotherapy of L1210 and

Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2′-deoxycytidine and β-2′-deoxythioguanosine

✍ Richard L. Momparler; Louise F. Momparler; Johanne Samson 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 French ⚖ 359 KB

## Abstract The __in vitro__ and __in vivo__ antineoplastic activity of 5‐AZA‐2'‐deoxycytidine (5‐AZA‐CdR) and β‐2‐deoxythioguanosine (TGdR) on L1210 an L1210/ARA‐C (resistant to cytosine arabinoside) leukemic cells was investigated. 5‐AZA‐CdR was a very potent cytotoxic agent against the L1210 leu